Background: DM patients have a 7-8 times higher risk of development of NASH with advanced fibrosis or cirrhosis than non-DM, which are predictors of mortality in NASH patients. This study evaluated mortality in NAFLD/NASH patients by liver disease severity and DM status.

Methods: This was a retrospective study from 2007-2015 of a 20% sample of U.S. Medicare beneficiaries and included NAFLD/NASH-DM patients (ICD codes/medications). Survival analyses performed via Kaplan-Meier curves for incidences of all-cause mortality and disease progression.

Results: This study identified NAFLD/NASH-DM patients: 100,098 with NAFLD/NASH only, 2,520 compensated cirrhosis (CC), 45,881 decompensated cirrhosis (DCC), 408 liver transplant (LT), and 384 hepatocellular carcinoma (HCC). Rates of comorbidities were high (at least 71% with cardiovascular disease). In 1 year, mortality was higher in DCC patients (18.1%) than in CC (4.3%) and NAFLD/NASH only (2.1%) (Figure). This trend continued over the study period. Liver disease progression was higher in CC patients with DM compared to no DM (20% vs. 17%).

Conclusions: NAFLD/NASH-DM patients overall mortality rate of 25.1% was 2-times higher than the expected rate for similarly aged general population of 12.7% (Social Security life table) over 8-year the study period.


R. Loomba: Consultant; Self; Eli Lilly and Company, Novo Nordisk Inc. J. Fraysse: Employee; Self; Gilead Sciences, Inc. S. Li: Consultant; Self; Gilead Sciences, Inc. A. Ozbay: Employee; Self; Gilead Sciences, Inc. Stock/Shareholder; Self; Gilead Sciences, Inc. S.A. Harrison: Advisory Panel; Self; Gilead Sciences, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at